KaydedilenlerDerginizi ekleyin

Dergiler / Üroonkoloji Bülteni / 2019 / Cilt: 18 - Sayı: 2

Nuclear Medicine Applications in Diagnosis of Urological Tumors

Mine ARAZ
Yüksel ÜRÜN
Sayfa
80–88
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Keywords: Urological neoplasms, radionuclide imaging, radiology

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Except for prostate carcinoma, there is limited data in the literature on the role of nuclear imaging methods in the management of urological cancers. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is generally the most widely used method in oncological imaging.
📊
Temel Bulgular & Veri:For this reason, some other 18F-labeled molecules, especially Ga-68 prostate-specific membrane antigen for prostate cancer and 18F-sodium fluoride for bone metastases, have recently gained importance.
💡
Sonuç & Katkı:Keywords: Urological neoplasms, radionuclide imaging, radiology
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Except for prostate carcinoma, there is limited data in the literature on the role of nuclear imaging methods in the management of urological cancers. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is generally the most widely used method in oncological imaging. However, the diagnostic power of this radiopharmaceutical in urological tumors is weakened partially due to its physiological urinary excretion. For this reason, some other 18F-labeled molecules, especially Ga-68 prostate-specific membrane antigen for prostate cancer and 18F-sodium fluoride for bone metastases, have recently gained importance. In addition, characterization of renal masses with Tc-99m methoxy isobutyl isonitrile (MIBI), a nonspecific tumor agent, and detection of bone metastases with whole-body Tc-99m methylene diphosphonate (MDP) bone scintigraphy are still used. In this review, scintigraphic methods and PET/CT imaging used in diagnosis and follow-up of urological tumors will be discussed. Keywords: Urological neoplasms, radionuclide imaging, radiology

🔖

Bu Makaleye Atıf Yap

ARAZ, M., ÜRÜN, Y. (2019). Nuclear Medicine Applications in Diagnosis of Urological Tumors. Üroonkoloji Bülteni, Cilt: 18 - Sayı: 2, 80–88. https://ajindex.com/articles/327905

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Bagheri MH, Ahlman MA, Lindenberg L et al. Advances in medical imaging for the diagnosis and management of common genitourinary cancers. Urol Oncol 2017
  2. [doi: 10.1016/j. urolonc.2017.04.014] 2. Kamel EM, Jichlinski P, Prior JO et al. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med 2006
  3. Ozülker T, Ozülker F, Ozbek E et al. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/ computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun 2011
  4. Ferda J Ferdova E, Hora M et al. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. Anticancer Res 2013
  5. Kang DE, White RL, Zuger JH, et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004
  6. Wang HY, Ding HJ, Chen JH, et al. Meta-analysis of the diagnostic performance of [18F] FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 2012
  7. Ma H, Shen G, Liu B et al. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun 2017
  8. 163 8. Ozülker T, Ozülker F, Ozbek E, et al. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/ computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun 2011
  9. 272 9. de Llano S RM, Jiménez-Vicioso A, Mahmood S, et al. Clinical impact of (18)F-FDG PET in management of patients with renal cell carcinoma. Rev Esp Med Nucl 2010
  10. Kumar R, Shandal V, Shamim SA, et al. Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun 2010
  11. Alongi P, Picchio M, Zattoni F, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging 2016
  12. 473 12. Revheim ME, Winge-Main AK, Hagen G, et al. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol 2011
  13. Vercellino L, Bousquet G, Baillet G, et al. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009
  14. Caldarella C, Muoio B, Isgrò MA, et